Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques
PRAGUE, Melanie
Statistics In System biology and Translational Medicine [SISTM]
Bordeaux population health [BPH]
Statistics In System biology and Translational Medicine [SISTM]
Bordeaux population health [BPH]
THIEBAUT, Rodolphe
Statistics In System biology and Translational Medicine [SISTM]
Bordeaux population health [BPH]
< Réduire
Statistics In System biology and Translational Medicine [SISTM]
Bordeaux population health [BPH]
Langue
EN
Article de revue
Ce document a été publié dans
Nature Communications. 2021-09-01, vol. 12, n° 1, p. 5215
Résumé en anglais
Achieving sufficient worldwide vaccination coverage against SARS-CoV-2 will require additional approaches to currently approved viral vector and mRNA vaccines. Subunit vaccines may have distinct advantages when immunizing ...Lire la suite >
Achieving sufficient worldwide vaccination coverage against SARS-CoV-2 will require additional approaches to currently approved viral vector and mRNA vaccines. Subunit vaccines may have distinct advantages when immunizing vulnerable individuals, children and pregnant women. Here, we present a new generation of subunit vaccines targeting viral antigens to CD40-expressing antigen-presenting cells. We demonstrate that targeting the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein to CD40 (alphaCD40.RBD) induces significant levels of specific T and B cells, with long-term memory phenotypes, in a humanized mouse model. Additionally, we demonstrate that a single dose of the alphaCD40.RBD vaccine, injected without adjuvant, is sufficient to boost a rapid increase in neutralizing antibodies in convalescent non-human primates (NHPs) exposed six months previously to SARS-CoV-2. Vaccine-elicited antibodies cross-neutralize different SARS-CoV-2 variants, including D614G, B1.1.7 and to a lesser extent B1.351. Such vaccination significantly improves protection against a new high-dose virulent challenge versus that in non-vaccinated convalescent animals.< Réduire
Project ANR
Initiative for the creation of a Vaccine Research Institute
Développement de vaccins anti-SARS-CoV-2
Infrastructure nationale pour la modélisation des maladies infectieuses humaines - ANR-11-INBS-0008
Développement de vaccins anti-SARS-CoV-2
Infrastructure nationale pour la modélisation des maladies infectieuses humaines - ANR-11-INBS-0008
Unités de recherche